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AGA INSTITUTE
The following article contains new recommendations for colorectal cancer screening, the first set we have published since 2003 (Winawer S,
Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale—update based on new evidence.
Gastroenterology 2003;124:544–560.) The current recommendations have emerged through the participation of multiple national societies,
taking into consideration newly emerging technologies. Please note the US Multi-Society Task Force (USMTF) represents the American
Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy, and the American College of Gastro-
enterology. Commissioned originally by the American Cancer Society, this compendium will be published concurrently in CA: A Cancer Journal
for Clinicians and reprinted in the June issue of Radiology.
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In the United States, colorectal cancer (CRC) is the
third most common cancer diagnosed among men
and women and the second leading cause of death
from cancer. CRC largely can be prevented by the
detection and removal of adenomatous polyps, and
survival is significantly better when CRC is diagnosed
while still localized. In 2006 to 2007, the American
Cancer Society, the US Multi-Society Task Force on
Colorectal Cancer, and the American College of Ra-
diology came together to develop consensus guide-
lines for the detection of adenomatous polyps and
CRC in asymptomatic average-risk adults. In this up-
date of each organization’s guidelines, screening tests
are grouped into those that primarily detect cancer
early and those that can detect cancer early and also
can detect adenomatous polyps, thus providing a
greater potential for prevention through polypec-
tomy. When possible, clinicians should make patients
aware of the full range of screening options, but at a
minimum they should be prepared to offer patients a
choice between a screening test that primarily is ef-
fective at early cancer detection and a screening test
that is effective at both early cancer detection and
cancer prevention through the detection and removal
of polyps. It is the strong opinion of these 3 organi-
zations that colon cancer prevention should be the
primary goal of screening.
In the United States, colorectal cancer (CRC) is thethird most common cancer diagnosed in men and
women and the second leading cause of death from
cancer.1 In 2008, it is estimated that 148,810 men and
women will be diagnosed with CRC and 49,960 will die
from this disease.1 Five-year survival is 90% if the disease
is diagnosed while still localized (ie, confined to the wall
of the bowel) but only 68% for regional disease (ie, disease
Abbreviations used in this paper: ACR, American College of Radiol-
ogy; ACRIN, American College of Radiology Imaging Network; ACS,
American Cancer Society; CRC, colorectal cancer; CSPY, colonoscopy;
CT, computed tomography; CTC, computed tomographic colonogra-
phy; DCBE, double-contrast barium enema; DIA, DNA integrity analysis;
FIT, fecal immunochemical test; FOBT, fecal occult blood test; FSIG,
flexible sigmoidoscopy; gFOBT, guaiac-based fecal occult blood test;
HPNCC, hereditary nonpolyposis colon cancer; MRI, magnetic reso-
nance imaging; NRDR, National Radiology Data Register; OC, optical
colonoscopy; sDNA, stool DNA test; 2D, 2-dimensional; 3D, 3-dimen-
sional; USMSTF, US Multi-Society Task Force on Colorectal Cancer.
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with lymph node involvement) and only 10% if distant
metastases are present.2 Recent trends in CRC incidence
and mortality reveal declining rates, which have been
attributed to reduced exposure to risk factors, the effect
of screening on early detection and prevention through
polypectomy, and improved treatment.3 However, in the
near term, even greater incidence and mortality reduc-
tions could be achieved if a greater proportion of adults
received regular screening. Although prospective ran-
domized trials and observational studies have demon-
strated mortality reductions associated with early detec-
tion of invasive disease, as well as removal of
adenomatous polyps,4–7 a majority of US adults are not
receiving regular age- and risk-appropriate screening or
have never been screened at all.8,9
The goal of cancer screening is to reduce mortality
through a reduction in incidence of advanced disease. To
this end, modern CRC screening can achieve this goal
through the detection of early-stage adenocarcinomas
and the detection and removal of adenomatous polyps,
the latter generally accepted as a nonobligate precursor
lesion. Adenomatous polyps are common in adults over
age 50 years, but the majority of polyps will not develop
into adenocarcinoma; histology and size determine their
clinical importance.10,11 The most common and clinically
important polyps are adenomatous polyps, which repre-
sent approximately one half to two thirds of all colorectal
polyps and are associated with a higher risk of CRC.
Thus, most CRC screening studies evaluate the detection
rate of invasive CRCs as well as advanced adenomas,
which conventionally are defined as polyps 10 mm or
histologically having high-grade dysplasia or significant
villous components. The evidence for the importance of
colorectal polyps in the development of CRC is largely
indirect, but nonetheless extensive and convincing, and
has been described in detail.11–13
Today there is a range of options for CRC screening in
the average-risk population, with current technology fall-
ing into 2 general categories: stool tests, which include
tests for occult blood or exfoliated DNA, and structural
exams, which include flexible sigmoidoscopy (FSIG),
colonoscopy (CSPY), double-contrast barium enema
(DCBE), and computed tomographic colonography
(CTC). Stool tests are best suited for the detection of
cancer, although they also will deliver positive findings
for some advanced adenomas, while the structural exams
can achieve the dual goals of detecting adenocarcinoma
as well as identifying adenomatous polyps.14 These tests
may be used alone or in combination to improve sensi-
tivity or, in some instances, to ensure a complete exam-
ination of the colon if the initial test cannot be com-
pleted. Although screening tests for CRC vary in terms of
the degree of supporting evidence, potential efficacy for
incidence and mortality reduction, cost-effectiveness, and
acceptability, any one of these options applied in a sys-
tematic program of regular screening has the potential to
significantly reduce deaths from CRC.
Beginning in 1980, the American Cancer Society (ACS)
first issued formal guidelines for CRC screening in aver-
age-risk adults.15 Since then, the ACS has periodically
updated its CRC guidelines,16–19 including adding rec-
ommendations for high-risk individuals in 1997.17 Other
organizations also have issued recommendations for
CRC screening, most notably the US Preventive Services
Task Force,20,21 the American College of Radiology
(ACR),22,23 and the US Multi-Society Task Force on Colo-
rectal Cancer (USMSTF).12,24 Recently, the ACS and the
USMSTF collaborated on an update of earlier recommen-
dations for postpolypectomy and post-CRC resection
surveillance in response to reports suggesting significant
deviation from existing recommendations.25,26 Since
1997, the organizational guidelines for average-risk
adults have grown increasingly similar and represent a
broad organizational consensus on the value, options,
and methods for periodic screening for CRC.
In the last decade, there has been an increase in the
number of technologies available for CRC screening, and
in the case of stool tests, there has been growth in the
number of commercial versions of guaiac-based and im-
munochemical-based stool tests (gFOBT and FIT). This
growth in options also has been accompanied by chang-
ing patterns in the proportion of adults using different
tests, with FSIG rates declining, CSPY rates increasing,
use of stool blood tests remaining somewhat constant,
and use of the DCBE for screening now becoming very
uncommon.8
There are pros and cons to having a range of options
for CRC screening. Despite the fact that the primary
barriers to screening are lack of health insurance, lack of
physician recommendation, and lack of awareness of the
importance of CRC screening,27 the historical evidence
shows that adults have different preferences and patterns
of use among the available CRC screening tests.28–31
Although population preferences or resistance to a par-
ticular technology may change over time or may be in-
fluenced by referring physicians, it also may be true that
over time some adults may persist in choosing one tech-
nology and rejecting another. Furthermore, at this time
not all options are available to the entire population, and
transportation, distance, and financial barriers to some
screening technologies may endure for some time. Al-
though in principle all adults should have access to the
full range of options for CRC screening, the fact that
simpler, lower-cost options are available in most settings,
whereas other more costly options are not universally
available, is a public health advantage. However, for av-
erage-risk adults, multiple testing options challenge the
referring physician to support an office policy that can
manage a broad range of testing choices, their follow-up
requirements, and shared decision making related to the
options. Shared decision making for multiple screening
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choices is both demanding and time consuming and is
complicated by the different characteristics of the tests
and the test-specific requirements for individuals under-
going screening.31 In addition, the description of benefits
is complicated by different performance characteristics of
the variants of the occult blood tests and uncertain
differences between test performance in research settings
and test performance in clinical practice. These chal-
lenges have been discussed in the past,19,32 and they still
are with us today.
In this guideline review, we have reassessed the indi-
vidual test evidence and comparative evidence for stool
tests, including gFOBT, FIT, and stool DNA test (sDNA),
and the structural exams, including FSIG, CSPY, DCBE,
and CTC, the latter also known as virtual colonoscopy.
We have sought to address a number of concerns about
the complexity of offering multiple screening options
and the degree to which the range of screening options
and their performance, costs, and demands on individu-
als poses a significant challenge for shared decisions. An
overriding goal of this update is to provide a practical
guideline for physicians to assist with informed decision
making related to CRC screening. These guidelines are
for individuals at average risk. Individuals with a per-
sonal or family history of CRC or adenomas, inflamma-
tory bowel disease, or high-risk genetic syndromes should
continue to follow the most recent recommendations for
individuals at increased or high risk.24–26
Guidelines Development, Methods, and
Framework
The guidelines update process was divided into 2
phases. The first phase focused on the stool tests, includ-
ing gFOBT, FIT, and sDNA. The second phase of the
guidelines update process focused on the structural ex-
ams, including FSIG, colonoscopy, DCBE,and CTC. De-
liberations about evidence and presentations from ex-
perts took place during 2 face-to-face meetings of the the
collaborating organizations and invited outside experts
and through periodic conference calls. The process relied
on earlier evidence-based reviews.12,16–21,24 Literature re-
lated to CRC screening and specific to individual tests
published between January 2002 and March 2007 was
identified using MEDLINE (National Library of Medi-
cine) and bibliographies of identified articles. Expert
panel members also provided several unpublished ab-
stracts and manuscripts. Where evidence was insufficient
or lacking to provide a clear, evidence-based conclusion,
final recommendations were based on expert opinion and
are so indicated.
While there is clear experimental evidence that screen-
ing for CRC with gFOBT is associ-ated with reduced
incidence and mortality from CRC screening,5,6,33 most
of the information supporting the use of the other colo-
rectal screening tests is based on observational and infer-
ential evidence. In this review, priority was placed on
studies of asymptomatic average-risk or higher-risk pop-
ulations that were followed by testing with colonoscopy
in all or nearly all study participants as a validation
measure.
Summary of the Recommendations
In this update of guidelines for CRC screening in
average-risk adults, the expert panel concluded that a
screening test must be able to detect the majority of
prevalent or incident cancers at the time of testing. Here
we are drawing a new, important distinction between test
sensitivity and program sensitivity, the former being the
sensitivity achieved in a single test and the latter being
the sensitivity achieved over time through serial testing in
a program. While cancer screening tests are expected to
achieve acceptable levels of sensitivity and specificity,34
no specific acceptance threshold for either measure, alone
or in combination, has been established for any screening
test.35,36 Thus, this criterion is based on expert opinion
and the following considerations. First, in the judgment
of the panel, recent evidence has revealed an unacceptably
wide range of sensitivity among some gFOBT strategies,
with some practices and tests performing so poorly that
the large majority of prevalent cancers are missed at the
time of screening.37–39 The observation of very low sen-
sitivity for cancer and advanced neoplasia associated with
in-office gFOBT led Sox to speculate that CRC mortality
rates might be considerably lower today if the quality of
gFOBT testing during the previous decade had been
higher.40 While the literature on other CRC screening
tests also reveals a range of sensitivities, even in the
presence of significant, correctable, quality-related short-
comings, the majority of invasive cancers still will be
detected. Second, a test like gFOBT that demonstrates
poor test sensitivity but good program sensitivity de-
pends on high rates of adherence with regular screening.
However, many patients have only one test and do not
return the following year for programmatic testing.41,42
Given the lack of systems to ensure or at least facilitate
adherence with recommended regular screening intervals,
as well as evidence of suboptimal awareness and engage-
ment of primary care in supporting adherence with
screening recommendations,43 the panel concluded that
it was not realistic at this time to rely on program
sensitivity to overcome limitations in test sensitivity. Phy-
sicians and institutions should select stool blood tests
that have been shown in the scientific literature to detect
the majority of prevalent CRCs in an asymptomatic pop-
ulation. If there is not evidence that an available test has
met that benchmark, it should not be offered to patients
for CRC screening.
Individuals and health care professionals should also
understand that screening tests for CRC broadly fall into
2 categories. In one category are the fecal tests (ie,
gFOBT, FIT, and sDNA), which are tests that primarily
are effective at identifying CRC. Some premalignant ad-
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enomatous polyps may be detected, providing an oppor-
tunity for polypectomy and the prevention of CRC, but
the opportunity for prevention is both limited and inci-
dental and is not the primary goal of CRC screening with
these tests. In the second category are the partial or full
structural exams (ie, FSIG, CSPY, DCBE, and CTC)44
which are tests that are effective at detecting cancer and
premalignant adenomatous polyps. These tests differ in
complexity and accuracy for the detection of CRC and
advanced neoplasia. When performed properly, each of
these structural exams has met the standard of detecting
at least half of prevalent or incident cancers at the time of
testing.
It is the strong opinion of this expert panel that colon
cancer prevention should be the primary goal of CRC
screening. Tests that are designed to detect both early
cancer and adenomatous polyps should be encouraged if
resources are available and patients are willing to un-
dergo an invasive test. These tests include the partial or
full structural exams mentioned above. These tests re-
quire bowel preparation and an office or hospital visit
and have various levels of risk to patients. These tests also
have limitations, greater patient requirements for suc-
cessful completion, and potential harms. Significant pos-
itive findings on FSIG, DCBE, and CTC require follow-up
CSPY.
The panel recognized that some patients will not want
to undergo an invasive test that requires bowel prepara-
tion, may prefer to have screening in the privacy of their
home, or may not have access to the invasive tests due to
lack of coverage or local resources. Collection of fecal
samples for blood or DNA testing can be performed at
home without bowel preparation. However, providers
and patients should understand the following limita-
tions and requirements of noninvasive tests:
&# These tests are less likely to prevent cancer com-
pared with the invasive tests;
&# These tests must be repeated at regular intervals to
be effective;
&# If the test is abnormal, an invasive test (CSPY) will
be needed.
If patients are not willing to have repeated testing or
have CSPY if the test is abnormal, these programs will
not be effective and should not be recommended.
Based on our review of the historic and recent evi-
dence, the tests in Table 1 are acceptable options for the
early detection of CRC and adenomatous polyps for
asymptomatic adults aged 50 years and older (also see
Table 2).
Screening Tests for the Detection of
CRC
Stool Blood Tests—gFOBT and FIT
Stool blood tests are conventionally known as
fecal occult blood tests (FOBT) because they are designed
to detect the presence of occult blood in stool. FOBT fall
into 2 primary categories based on the detected analyte:
gFOBT and FIT. Blood in the stool is a nonspecific
finding but may originate from CRC or larger (1 to 2
cm) polyps. Because small adenomatous polyps do not
tend to bleed and bleeding from cancers or large polyps
may be intermittent or simply not always detectable in a
single sample of stool, the proper use of stool blood tests
requires annual testing that consists of collecting speci-
mens (2 or 3, depending on the product) from consecu-
tive bowel movements.18,24,45 FIT generally are processed
only in a clinical laboratory, whereas gFOBT are pro-
cessed either in the physician’s office or in a clinical
laboratory. When performed for CRC screening, a posi-
tive gFOBT or FIT requires a diagnostic workup with
CSPY to examine the entire colon in order to rule out the
presence of cancer or advanced neoplasia.
gFOBT
gFOBT are the most common stool blood tests in
use for CRC screening and the only CRC screening tests
for which there is evidence of efficacy from prospective,
randomized controlled trials. Guaiac-based tests detect
blood in the stool through the pseudoperoxidase activity
of heme or hemoglobin, while immunochemical-based
tests react to human globin. The usual gFOBT protocol
consists of collecting 2 samples from each of 3 consecu-
tive bowel movements at home. Prior to testing with a
sensitive guaiac-based test, individuals usually will be
instructed to avoid aspirin and other nonsteroidal anti-
inflammatory drugs, vitamin C, red meat, poultry, fish,
and some raw vegetables because of diet-test interactions
that can increase the risk of both false-positive and false-
negative (specifically, vitamin C) results.46 Collection of
all 3 samples is important because test sensitivity im-
proves with each additional stool sample.14
gFOBT—Efficacy and Test Performance. Three
large, prospective, randomized controlled trials with
gFOBT have demonstrated that screened patients have
cancers detected at an early and more curable stage than
unscreened patients. Over time (8–13 years), each of the
Table 1. Testing Options for the Early Detection of
Colorectal Cancer and Adenomatous Polyps for
Asymptomatic Adults Aged 50 Years and Older
Tests that detect adenomatous polyps and cancer
FSIG every 5 years, or
CSPY every 10 years, or
DCBE every 5 years, or
CTC every 5 years
Tests that primarily detect cancer
Annual gFOBT with high test sensitivity for cancer, or
Annual FIT with high test sensitivity for cancer, or
sDNA, with high sensitivity for cancer, interval uncertain
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trials demonstrated significant reductions in CRC mor-
tality of 15% to 33%.5,6,34 Moreover, incidence reduction
of 20% was demonstrated in one trial (Minnesota) after
18 years of follow-up, which has been attributed to rela-
tively higher rates of CSPY in the study (38% of subjects
in the screened group).7
The sensitivity and specificity of a gFOBT has been
shown to be highly variable and varies based on the brand
or variant of the test;47 specimen collection technique;38
number of samples collected per test;14 whether or not the
stool specimen is rehydrated (ie, adding a drop of water to
the slide window before processing);48; and variations in
interpretation, screening interval, and other factors.46
The reported sensitivity of a single gFOBT varies con-
siderably. In a review by Allison and colleagues, sensitivity
for cancer ranged from 37.1% for unrehydrated Hemoc-
Table 2. Guidelines for Screening for the Early Detection of Colorectal Cancer and Adenomas for Average-risk Women and
Men Aged 50 Years and Older
The following options are acceptable choices for colorectal cancer screening in average-risk adults beginning at age 50 years. Since each of
the following tests has inherent characteristics related to prevention potential, accuracy, costs, and potential harms, individuals should
have an opportunity to make an informed decision when choosing one of the following options.
In the opinion of the guidelines development committee, colon cancer prevention should be the primary goal of colorectal cancer screening.
Tests that are designed to detect both early cancer and adenomatous polyps should be encouraged if resources are available and
patients are willing to undergo an invasive test.
Tests that Detect Adenomatous Polyps and Cancer
Test Interval Key Issues for Informed Decisions
FSIG with insertion to 40 cm or to
splenic flexure
Every 5 years ● Complete or partial bowel prep is required
● Sedation usually is not used, so there may be some discomfort during the
procedure
● The protective effect of sigmoidoscopy is primarily limited to the portion of
the colon examined
● Patients should understand that positive findings on sigmoidoscopy
usually result in a referral for CSPY
CSPY Every 10 years ● Complete bowel prep is required
● Conscious sedation is used in most centers; patients will miss a day of
work and will need a chaperone for transportation from the facility
● Risks include perforation and bleeding, which are rare but potentially
serious; most of the risk is associated with polypectomy
DCBE Every 5 years ● Complete bowel prep is required
● If patients have one or more polyps 6 mm, CSPY will be recommended;
follow-up CSPY will require complete bowel prep
● Risks of DCBE are very low; rare cases of perforation have been reported
CTC Every 5 years ● Complete bowel prep is required
● If patients have one or more polyps 6 mm, CSPY will be recommended;
if same day CSPY is not available, a second complete bowel prep will be
required before CSPY
● Risks of CTC are very low; rare cases of perforation have been reported
Tests that Primarily Detect Cancer
Test Interval Key Issues for Informed Decisions
gFOBT with high sensitivity for cancer Annual ● Depending on manufacturer’s recommendations, 2 to 3 stool samples
collected at home are needed to complete testing; a single sample of
stool gathered during a digital exam in the clinical setting is not an
acceptable stool test and should not be done
FIT with high sensitivity for cancer Annual ● Positive tests are associated with an increased risk of colon cancer and
advanced neoplasia; CSPY should be recommended if the test results are
positive
● If the test is negative, it should be repeated annually
● Patients should understand that one-time testing is likely to be ineffective
sDNA with high sensitivity for cancer Interval uncertain ● An adequate stool sample must be obtained and packaged with
appropriate preservative agents for shipping to the laboratory
● The unit cost of the currently available test is significantly higher than
other forms of stool testing
● If the test is positive, CSPY will be recommended
● If the test is negative, the appropriate interval for a repeat test is
uncertain
FSIG, flexible sigmoidoscopy; CSPY, colonoscopy; DCBE, double-contrast barium enema; CTC, computed tomography colonography; gFOBT,
guaiac-based fecal occult blood test; FIT, fecal immunochemical test; sDNA, stool DNA test.
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cult II to 79.4% for Hemoccult SENSA.47 Lieberman and
Weiss compared one-time testing with rehydrated
Hemoccult II and observed 35.6% sensitivity for cancer.14
In a study comparing gFOBT (unrehydrated Hemoccult
II) with sDNA, sensitivity for cancer was only 12.9%.37
More recently, Allison and colleagues compared a high-
sensitivity gFOBT (Hemoccult SENSA) with an FIT and
observed 64.3% sensitivity for cancer and 41.3% for ad-
vanced adenomas.49 Thus, the data reveal a range of
performance among gFOBT variants that allows them to
be grouped into low and high test sensitivity groups. The
specificity of gFOBT also is variable, with low test sensi-
tivity gFOBT (such as Hemoccult II) tending to have very
high specificity and high test sensitivity gFOBT (such as
Hemoccult SENSA) having lower specificity. In a com-
parison of various stool blood tests, Allison and col-
leagues observed specificity for cancer and advanced ad-
enomas of 97.7% and 98.1%, respectively, for Hemoccult
II, with a combined specificity for cancer and advanced
adenomas of 98.1%. For Hemoccult SENSA, which had
greater sensitivity for cancer and advanced adenomas
compared with Hemoccult II, specificity for cancer and
advanced adenomas was 86.7% and 87.5%, respectively,
with a combined specificity for cancer and advanced
adenomas of 87.5%.47
A significant limitation of the potential of testing with
gFOBT is that it is commonly performed in the physi-
cian’s office as a single-panel test following a digital rectal
exam.39 In a recent national survey of primary care phy-
sicians, 31.2% reported using only the in-office method of
gFOBT, and an additional 41.2% of physicians reporting
using both the in-office method or the take-home
method. While this approach may seem pragmatic, Col-
lins et al demonstrated that sensitivity is only 4.9% for
advanced neoplasia and only 9% for cancer.38 The accu-
racy of this method is so low that it cannot, under any
circumstances or rationale of convenience, be endorsed as
a method of CRC screening.
An additional limitation observed in the current use of
gFOBT is inadequate follow-up of a positive test. Despite
the fact that all existing CRC screening guidelines rec-
ommend CSPY follow-up of a positive gFOBT, in the
same survey that revealed high rates of in-office gFOBT,
nearly one third of physicians reported that they followed
up a positive gFOBT with a repeat gFOBT, and a sub-
stantial percentage reported that they referred patients to
sigmoidoscopy rather than CSPY after a positive gFOBT.
Similar patterns of testing and response to positive test
results have been reported by patients undergoing at-
home screening.39
gFOBT—Benefits, Limitations, and Harms. An-
nual testing with gFOBT has been shown to reduce both
CRC mortality and incidence. Testing for occult blood is
simple and is associated with minimal harm, although
any testing with gFOBT is associated with a possibility of
a positive test result that will require follow-up with
CSPY, which is associated with a greater risk of harm.
The limitation of gFOBT is that many of the individual
tests have limited test sensitivity under the best of cir-
cumstances, and this sensitivity may be further compro-
mised by poor and incomplete specimen collection and
inadequate or improper processing and interpretation.
Program sensitivity (ie, the outcome of repeat annual
testing) is considerably higher, but the systems to ensure
regular annual testing often are not in place to support
either the patient or his or her physician to be adherent.
Further, testing in the office following a digital rectal
exam, which is highly inaccurate, has been common and
still may persist at significant levels today. When the test,
the testing procedure, or both have very low test sensi-
tivity, and when positive tests are not followed up with
CSPY, the potential is high for patients to have a false
sense of reassurance after testing. Finally, patients who
choose gFOBT for CRC screening must understand that
annual testing is required.
Quality Assurance. If patients and their provid-
ers select gFOBT for CRC screening, they should be
aware of several quality issues based on programmatic
performance in clinical trials. First, the test must be
performed properly with 3 stool samples obtained at
home. A single stool sample FOBT collected after digital
rectal exam in the office is not an acceptable screening
test, and it is not recommended. Prior to testing with a
sensitive guaiac-based test, individuals should be in-
structed to avoid nonsteroidal anti-inflammatory drugs
such as ibuprofen, naproxen, or aspirin (more than one
adult aspirin per day) for 7 days prior to testing unless
they are on a cardioprotective regimen. There has been
debate as to whether additional dietary restrictions re-
duce compliance with testing and are necessary to reduce
the risk of both false-negative and false-positive results.
Results of a meta-analysis that examined completion and
positivity results found little support for the influence of
dietary restrictions on completion or positivity rates,
with the exception of completion rates in one study that
imposed severe restrictions. However, manufacturers still
endorse avoidance of vitamin C in excess of 250 mg from
either supplements or citrus fruits and juices and avoid-
ance of red meats (beef, lamb, and liver) for 3 days before
testing. This seems prudent since recent consumption of
red meat is associated with increased false positivity, and
excess vitamin C can result in false-negative results. Sec-
ond, it is critically important that physician offices and
laboratories follow recommended quality assurance pro-
cedures for test development and interpretation. Al-
though rehydration of gFOBT slides increases sensitivity,
it is not recommended because it can adversely affect the
readability of the test and also substantially increases the
false-positive rate. Sinatra and colleagues observed con-
siderable variation in the interpretation of gFOBT among
13 laboratories in Melbourne, Australia, and concluded
that ongoing technician training and review of laboratory
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procedures were important.50 Better results may be
achieved if guaiac-based tests are routinely processed and
interpreted in a clinical laboratory. Third, if the test is
positive, patients should be advised to have CSPY. Re-
peating the stool test or follow-up with non-CSPY tests is
inappropriate. Fourth, if the test result is negative, pa-
tients should understand that they need to have repeated
testing annually.
gFOBT—Conclusions and Recommendations. An-
nual screening with high-sensitivity gFOBT (such as
Hemoccult SENSA) that have been shown in the pub-
lished peer-reviewed literature to detect a majority of
prevalent CRC in an asymptomatic population is an
acceptable option for colorectal screening in average-risk
adults aged 50 years and older. Any positive test should
be followed up with CSPY. Individuals should be in-
formed that annual testing is necessary to achieve the
fullest potential of this test and that they will need
follow-up CSPY if test results are positive. Screening for
CRC with gFOBT in the office following digital rectal
exam or as part of a pelvic examination is not recom-
mended and should not be done. Commonly used guaiac
tests, with or without rehydration, that have not been
shown in the literature to detect a majority of prevalent
CRC at the time of testing are no longer recommended.
FIT
The concept of applying an immunochemical
method to testing stool for occult blood was first pro-
posed in the 1970s,51 and commercialization of the tech-
nology began in the 1980s. The use of FIT in the United
States has lagged behind some other countries, mostly
due to the higher costs associated with FIT compared
with gFOBT. However, recently increased reimbursement
by Medicare made the use of FIT financially viable and
has led to its wider acceptability in the United States.52
FIT has several technological advantages when com-
pared with gFOBT. FIT detects human globin, a protein
that along with heme constitutes human hemoglobin.
Thus, FIT is more specific for human blood than guaiac-
based tests, which rely on detection of peroxidase in
human blood and also react to the peroxidase that is
present in dietary constituents such as rare red meat,
cruciferous vegetables, and some fruits.53 Further, unlike
gFOBT, FIT is not subject to false-negative results in the
presence of high-dose vitamin C supplements, which
block the peroxidase reaction. In addition, because globin
is degraded by digestive enzymes in the upper gastroin-
testinal tract, FIT also are more specific for lower gastro-
intestinal bleeding, thus improving their specificity for
CRC. Finally, the sample collection for some variants of
FIT are less demanding of patients than gFOBT, requir-
ing fewer samples or less direct handling of stool.
FIT—Efficacy and Test Performance. Recently, a
number of new FIT have entered the market, although
not all are available in the United States. Some of the new
FIT have been evaluated in comparison with gFOBT in
diagnostic accuracy studies with human subjects who all
undergo CSPY to define the true presence or absence of
neoplasia. Other FIT have been evaluated only on the
basis of their ability to detect the presence of certain
concentrations of blood in laboratory settings. No FIT
has been tested in a randomized trial where the outcome
of interest is CRC mortality, nor is it likely, as is the case
with CSPY, that such a study will ever be undertaken.
A number of studies over the past 20 years have com-
pared the diagnostic accuracy of various FIT with gFOBT
(most often Hemoccult II or Hemoccult SENSA). In this
review, we have focused on studies that compared differ-
ent FIT with Hemoccult SENSA since at present it has
the highest sensitivity of currently marketed gFOBT.49,54–58
Based on data from these 6 studies, it appears that there
are no clear patterns of superior performance in overall
test performance between a high-sensitivity guaiac-based
test (Hemoccult SENSA) and a variety of FIT.
FIT has been performed in subjects undergoing screen-
ing CSPY to determine one-time sensitivity and specific-
ity. Morikawa et al studied 21,805 asymptomatic adults
who underwent testing with the Magstream 1000 test
(not available in the United States), followed by CSPY.59
The Magstream FIT was positive in 5.6% of patients, with
27.1% sensitivity for advanced neoplasia and 65.8% sen-
sitivity for cancer. In a similar study, although not in a
totally asymptomatic population, Levi and colleagues
sought to measure both sensitivity and specificity of a
quantitative FIT and, as well, to measure fecal hemoglo-
bin thresholds most predictive of advanced neoplasia and
cancer.58 One thousand ambulatory patients, some with
and some without symptoms of CRC, who were sched-
uled for CSPY and who were willing to also undergo an
FIT with 3 samples were included in the study. The
hemoglobin content of 3 bowel movements was mea-
sured. The sensitivity for cancer with 3 FIT samples with
a hemoglobin threshold set at 75 ng/mL was 94.1%.
Specificity for cancer was 87.5%. Allison and colleagues
recently published results of a comparison of a sensitive
gFOBT (Hemoccult SENSA) with an FIT (Hemoccult
ICT) for cancer and advanced adenomas in the distal
colon in nearly 6000 average-risk subjects who had un-
dergone FSIG.49 Both tests showed superior sensitivity
for cancer compared with the single-test performance of
an unrehydrated gFOBT. The sensitivity for CRC of the
FIT and the sensitive gFOBT was 81.8% and 64.3%, re-
spectively. However, the sensitive gFOBT showed supe-
rior performance for advanced adenomas (41.3%) com-
pared with FIT (29.5%). Specificity of FIT tends to be
higher than that observed for high-sensitivity gFOBT.
For example, in the analysis by Allison et al, the specific-
ity of Hemoccult ICT was 96.9% for distal cancer, 97.3%
for distal advanced lesions, and 97.5% for all distal ad-
vanced neoplasia.49
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FIT—Benefits, Limitations, and Harms. The spec-
trum of benefits, limitations, and harms is similar to a
gFOBT with high sensitivity. One advantage of FIT over
gFOBT appears to be a function of fewer demands on
patients undergoing FIT compared with gFOBT. FIT
does not require a restricted diet, and the sampling pro-
cedures for some forms of FIT are less demanding.60
Quality Assurance. If patients and their provid-
ers select FIT, they should be aware of several quality
issues. Although there are no clinical trials assessing
programmatic performance, an effective screening pro-
gram will depend on repeat testing if the initial test is
negative and referral for CSPY if the test is positive. At
this time, the optimal number of FIT stool samples is not
established, but 2 samples may be superior to one.61
FIT—Other Issues. Given the lack of clear differ-
ence in test performance in studies conducted to date,
policy makers, providers, and patients may want to con-
sider other factors when deciding which occult blood test
to use. Relevant other factors include cost (both out-of-
pocket and total costs) and likelihood of test completion,
which appears to be greater with FIT compared with
gFOBT.60
FIT—Conclusions and Recommendations. An-
nual screening with FIT that have been shown in the
published peer-reviewed literature to detect a majority of
prevalent CRC in an asymptomatic population at the
time of testing is an acceptable option for colorectal
screening in average-risk adults aged 50 years and older.
Any positive test should be followed up with CSPY.
Adults should be informed that annual testing is neces-
sary to achieve the fullest potential of this test and that
they will need follow-up CSPY if test results are positive.
sDNA
Knowledge of molecular genomics provides the
basis of a new method of CRC screening that tests stool
for the presence of known DNA alterations in the ade-
noma-carcinoma sequence of colorectal carcinogenesis.
Adenoma and carcinoma cells that contain altered DNA
are continuously shed into the large bowel lumen and
passed in the feces. Because DNA is stable in stool, it can
be differentiated and isolated from bacterial DNA found
in the feces.62 No single gene mutation is present in cells
shed by every adenoma or cancer. Thus, a multitarget
DNA stool assay is required to achieve adequate sensitiv-
ity. At present there is only one commercially available
sDNA test. The prototype assay of this test (version 1.0)
for which most of the published evidence is available
consisted of a multiple-marker panel that included 21
separate point mutations in the K-ras, APC, and P53
genes; a probe for BAT-26 (a marker of microsatellite
instability); and a marker of DNA integrity analysis
(DIA). The sDNA that is currently commercially available
is a second generation version of this test (version 1.1)
that includes this same marker panel but incorporates
several technical advances related to processing and spec-
imen preservation.63,64 Whereas gFOBT and FIT test a
sample of stool or sample of water surrounding stool, the
currently available sDNA test requires the entire stool
specimen (30-g minimum to ensure an adequate sample
of stool for evaluation). Collection kits have been de-
signed to facilitate specimen collection and mailing and
to enhance compliance.
sDNA—Efficacy and Test Performance. Several
studies on the sensitivity and specificity of sDNA testing
for CRC detection have been published utilizing a panel
of DNA markers.37,65–69 Test sensitivity for CRC in these
studies ranged from 52% to 91%, with specificity ranging
from 93% to 97%. Lower sensitivity in some of these
studies has been attributed to suboptimal sensitivity per-
formance of DIA resulting from DNA degradation dur-
ing transit of specimens to the laboratory. The changes
associated with version 1.1 are reported to address these
problems. One study utilizing version 1.1 has been pub-
lished by Whitney et al63 reporting a sensitivity for CRC
of 70%.
sDNA has been compared with a low-sensitivity
gFOBT in one large prospective study of an average-risk
screening cohort. Imperiale et al conducted an investiga-
tion in a cohort of 2507 average-risk individuals under-
going colorectal neoplasia screening by 3 modalities:
sDNA using the prototype assay (version 1.0), gFOBT
(nonrehydrated Hemoccult II), and CSPY.37 sDNA test-
ing had statistically significantly better sensitivity for
CRC compared with Hemoccult II (52% vs 13%) and for
all cancers and high-grade dysplasia (40.8% vs 14.1%),
with comparable specificity. In this study, sDNA was
much less sensitive in the detection of all advanced ade-
nomas (15.1%), defined as a tubular adenoma at least 1
cm in diameter, an adenoma with a villous histologic
appearance, or an adenoma with high-grade dysplasia,
although it still showed superior performance to the
comparison gFOBT (10.7%).37 Data on program perfor-
mance of sDNA screening are lacking. Information on
the sensitivity and specificity of CRC and adenoma de-
tection comes from an evaluation of results from a single
test. Also, the currently available sDNA gene test—version
1.1—has not been rigorously tested in screening cohorts
but based on available data can be reasonably assumed to
perform as well or better than Version 1.0.63 New version
assays with better DNA stabilization and simplified ge-
netic analyses may be more sensitive than version 1.0 but
require testing in screening cohorts.70
sDNA—Benefits, Limitations, and Harms. The
benefit of sDNA is that this methodology has acceptable
sensitivity for CRC and is built upon the concept of
detecting molecular markers associated with advanced
colorectal neoplasia. It is not dependent on the detection
of occult bleeding, which is intermittent and nonspecific,
and it requires only a single stool collection. Further,
newer versions may have better sensitivity as more is
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learned about markers that are common across all prev-
alent CRCs as well as advanced adenomas. sDNA sam-
pling also is noninvasive and lacks physical harm. Patient
and provider acceptance of this technique appears to be
high, with available data indicating that sDNA is pre-
ferred over other tests by some individuals, and among
others testing with sDNA, it is at least as acceptable to
patients as testing with gFOBT.29,71 Berger et al reported
that most individuals undergoing sDNA who completed
a mailed survey reported satisfaction with the sDNA
testing process, and most reported that they would re-
peat testing if recommended by their physician.72
A clear limitation of sDNA testing for the detection of
CRC and large adenomas is that test sensitivity is based
on a panel of markers that appears to identify the ma-
jority of but not all CRC. Further, it is not known what
proportion of advanced adenomas is identified with the
current commercial version (version 1.1) of the sDNA
test. Other potential limitations that have considerable
implications for cost-effectiveness are the unit cost of the
current test,73 which is much higher than the other stool
tests, and the frequency by which the test should be
performed, which is uncertain. Currently, the test is un-
der review by the Food and Drug Administration for
510K certification but is commercially available under
the in-house developed “home brew” category of labora-
tory tests.
An additional issue is the clinical relevance of a posi-
tive genetic test without identification of the cause of the
abnormality; this has not been studied systematically. At
issue for a test that is based on molecular markers is the
degree to which a positive test, with no evidence of
advanced lesions upon completion of CSPY, is truly neg-
ative or positive for a lesion that is not yet clinically
evident. Osborn and Ahlquist have highlighted the fact
that inasmuch as cancers exfoliate cells and that these
cells can survive the digestive process and ultimately be
excreted in stool, high-prevalence supracolonic aerodiges-
tive cancers may also be detected by sDNA.74 However, at
this time, the significance of a positive test result in a
patient with a negative follow-up evaluation is unknown.
Quality Assurance. Individuals should be in-
formed about the benefits and limitations of screening
for CRC with sDNA, including the fact that at present
the test is more sensitive for cancer than advanced ade-
nomas, that the current panel of markers will not identify
all cancers, and that a positive test will need to be fol-
lowed up with CSPY. Individuals should be made aware
that their stool specimen must be packaged and shipped
in a customized collection kit that includes a specially
designed ice pack. Patients must have access to a working
freezer and allow this ice pack to freeze for at least 8
hours prior to use. If the specimen is returned without
the ice pack or if there are unforeseen delays in specimen
return or processing, the specimen may be rejected.
sDNA—Other Issues. Testing stool for mutated
DNA and other markers poses unique challenges in
shared decision making. The panel of markers that was
evaluated in population studies was not sensitive for all
advanced lesions and cancer, and there is uncertainty
about improvements in the sensitivity of newer versions
for advanced neoplasia and cancer in screening cohorts.
At this time, patients will need to be informed that sDNA
will detect some but not all advanced lesions and cancers.
There also is uncertainty about how positive results with-
out evidence of advanced lesions or cancer on follow-up
should be interpreted by patients and whether or not
these patients require a different plan for ongoing sur-
veillance.75 Additional research is necessary to resolve
these questions.
As noted previously, the most informative data on the
performance of sDNA testing is from version 1.0, which
has been replaced with version 1.1; the newer version uses
the same panel of markers but is reported to have im-
proved quality.63,70 Newer versions are currently under
evaluation, and are reported to have improved sensitivity,
with diminution of specificity. The evolution of tests of
this type raises important questions as to how perfor-
mance of successive iterations should be evaluated and
whether large prospective studies of asymptomatic pa-
tients with follow-up CSPY among all participants are
required. Another question worthy of consideration is
whether or not including a sensitive gFOBT or FIT at the
time of testing would improve sensitivity without ad-
versely affecting specificity. In a recent retrospective anal-
ysis of stool samples from patients with CRC and donor
controls, combined results from a standard gFOBT and a
panel of DNA markers (APC, BAT26, and L-DNA) re-
sulted in a combined sensitivity for cancer of 93% and
specificity of 89%.76
sDNA—Conclusions and Recommendations. In
previous assessments of the performance of sDNA, both the
ACS and the USMSTF concluded that data were insuffi-
cient to recommend screening with sDNA for average-risk
individuals.19,24 Based on the accumulation of evidence
since the last update of these guidelines, the committee
concluded that there are now sufficient data to include
sDNA as an acceptable option for CRC screening. As noted
above, testing stool for molecular markers is an evolving
technology. New iterations of these tests, either technolog-
ical enhancements of existing tests or completely new test
variants, should be carefully evaluated in order to determine
that they meet the criteria of detecting a majority of cancers
at the time of screening but also have acceptable perfor-
mance in a screening cohort. While the manufacturer of the
one test that is commercially available currently is recom-
mending a 5-year interval for routine screening between
examinations with normal results, the committee con-
cluded that there were insufficient data upon which to
endorse this interval. Such an interval was judged by the
committee to be appropriate only for a test that has very
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high sensitivity for both cancer and adenomatous polyps—a
standard that has not been documented for sDNA to date.
At this time, further research is needed to determine the
interval between negative sDNA examinations. Based on
current evidence, the appropriate interval is uncertain.
Tests for the Detection of Adenomas
and CRC
Endoscopy Examinations of the Colon and
Rectum—FSIG and CSPY
FSIG. FSIG is an endoscopic procedure that ex-
amines the lower half of the colon lumen. In addition to
the standard 60-cm sigmoidoscope, the exam may be
performed with a variety of endoscopic instruments, in-
cluding a colonoscope, an upper endoscope, and a pedi-
atric colonoscope. It is typically performed without seda-
tion and with a more limited bowel preparation than
standard CSPY. Since sedation is not required, it can be
performed in office-based settings and by nonphysicians,
including nurses or physician assistants, provided ade-
quate training has been received.77
FSIG—Efficacy and Test Performance. The use of FSIG
for CRC screening is supported by high-quality case-
control and cohort studies, which have been reviewed in
detail elsewhere.24 In 2 well-known case-control studies,
FSIG was associated with a 60% to 80% reduction in CRC
mortality for the area of the colon within its reach, and
this protective effect appears to persist for 10 years or
more.4,78 A small, randomized trial79 and a case-control
study80 also demonstrated decreased CRC incidence in
the sigmoidoscopy-screened group compared with a non-
screened control group. There are 4 prospective, random-
ized controlled trials ongoing in the United States and
Europe,81–84 and results are expected in the near future.
Additional evidence supporting the effectiveness of
FSIG derives from CSPY studies. FSIG is 60% to 70% as
sensitive for advanced adenomas and cancers in the colon
compared with CSPY.85,86 However, this figure varies ac-
cording to age, with proximal neoplasia becoming more
common after age 65 years.87 Due to observed differences
in the distribution of colonic neoplasia, FSIG may also be
less sensitive in women than in men,88 although the
overall prevalence of advanced colonic neoplasia is lower
in women than in men,89 and it may be less sensitive in
African Americans than in Whites. Several studies have
indicated that African Americans have a higher preva-
lence of proximal lesions than Whites,90,91 although a
more recent evaluation of proximal lesions in a consec-
utive series of African American and White adults under-
going FSIG did not observe a statistically significant
difference in proximal lesions between the 2 groups
among those adults with neoplastic lesions identified
during sigmoidoscopy.92 In addition, a number of recent
studies have documented a lower prevalence of distal
colon and rectal lesions in Whites compared with His-
panics and Asians.92,93 Differences in the prevalence of
distal and proximal lesions based on age, gender, and
ethnicity and the benefits and limitations of CRC screen-
ing with FSIG among these different groups remain im-
portant areas for continued investigation.
The effectiveness of sigmoidoscopy depends on the
completion of a high-quality exam. Studies have demon-
strated variable adenoma detection rates at screening
sigmoidoscopy that are attributed to exam quality and
completeness.94 Advanced neoplasia has been found
within 3 years of a negative sigmoidoscopy in the Pros-
tate, Lung, Colorectal and Ovarian Cancer Screening
Trial, raising issues of exam quality.95 Although scope
insertion to beyond 40 cm is only one measure of quality,
the clinical studies that report adenoma detection and
efficacy all achieve this level of insertion.96 Studies have
demonstrated that deeper levels of insertion are associ-
ated with a higher detection rate for advanced neopla-
sia.86 Therefore, the panel recommends that if sigmoid-
oscopy is performed for CRC screening, insertion to 40
cm or beyond is required.
Exam quality also depends on the appropriate man-
agement of endoscopic findings. The panel recommends
that any endoscopist performing sigmoidoscopy should
be skilled in obtaining biopsies of polyps to determine
histology. The histologic findings are informative for
follow-up decision making. There is evidence from 2
large screening studies that if a patient has an adenoma
of any size in the distal colon, he or she has an increased
risk of proximal advanced neoplasia (2-fold or higher)
compared with patients who have no polyps or only
hyperplastic polyps in the distal colon.14,85 Therefore, we
recommend that most patients who have adenomas dis-
covered at sigmoidoscopy should undergo CSPY. If biop-
sies are not obtained, another strategy is to refer all
patients with one or more polyps 5 mm for CSPY.97
The appropriate interval between normal sigmoidos-
copy exams is uncertain and may extend to 10 years,
although the protective effect would depend greatly on
the quality of the examination. Prior ACS and USMSTF
CRC screening guidelines have recommended a 5-year
interval between normal FSIG examinations, while rec-
ommending a 10-year interval between CSPY examina-
tions.18,24 The shorter interval was recommended for
FSIG because of concerns about exam quality and com-
pleteness in most clinical settings. In settings where an
experienced endoscopist performs a complete examina-
tion on a well-prepared patient and achieves insertion
beyond 40 cm, a 10-year interval between screening FSIG
may be justified. Since these criteria are not routinely
achieved in many clinical settings, a 5-year rescreening
interval remains the standard recommendation.
The most important limitation in the evidence for
FSIG is the lack of a longitudinal head-to-head compar-
ison between FSIG screening and other CRC screening
tests, such as CSPY or the different stool blood tests.
Apart from the issue of patient preference, a key question
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for screening policy is the incremental benefit of CSPY
over FSIG, given the higher direct medical and indirect
costs of CSPY and the higher risk of complications with
CSPY.98
FSIG—Benefits, Limitations, and Harms. The chief ad-
vantage of FSIG is that it can be performed with a simple
preparation (2 Fleet enemas), without sedation, and by a
variety of examiners in diverse settings. With respect to
distal bowel cleansing, the use of enemas is often imper-
fect, and superior bowel cleansing is achieved with the
more thorough oral sodium phosphate procedure. Pa-
tients have reported a more favorable experience with the
oral preparation compared with the enemas.99 The ab-
sence of sedation is perceived by some patients as an
advantage and by others as a disadvantage, although in
one series a greater percentage of patients undergoing
sigmoidoscopy reported periprocedural discomfort (dur-
ing and postexam) compared with patients undergoing
CSPY.100 Moreover, lack of sedation is associated with
greater patient discomfort and greater patient reluctance
to undergo the examination for future screening.100
An additional limitation of FSIG is that there may be
considerable variation both in depth of insertion of the
scope and in adenoma detection at FSIG between differ-
ent examiners,94,101 and this may reduce the effectiveness
of FSIG for CRC screening, especially in practice settings
of low volume. Quality assurance is an important issue
for flexible sigmoidoscopists and has been reviewed in
detail elsewhere.77 Providers should be well trained and
should exceed the published American Society for Gas-
trointestinal Endoscopy standards for a minimum num-
ber of training examinations prior to performing sig-
moidoscopy without supervision.
The chief limitation of FSIG is that it does not exam-
ine the entire colon but, under optimal conditions, only
the rectum, sigmoid, and descending colon. However,
several lines of evidence support the idea that the incre-
mental benefit of CSPY is less than simply the difference
in sensitivity for advanced adenomas between CSPY and
FSIG because many patients with small distal adenomas
will receive CSPY, which may result in discovery of prox-
imal advanced adenomas and cancer. The complications
of FSIG include colonic perforation, even if no biopsy or
polypectomy is performed, but this occurs in fewer than
one in 20,000 examinations.82,102
Quality Assurance. Quality indicators for FSIG have
been previously published.77 Key elements include (1)
appropriate training of endoscopists; (2) satisfactory ex-
amination rates to beyond 40 cm; (3) expected adenoma
detection rates based on age and gender; and (4) ability to
biopsy suspected adenomas. The effectiveness of an FSIG
program is based on the assumption that if an adenoma
is detected in the sigmoid colon or rectum, the patient
would be referred for total CSPY. Patients should fully
understand that in most circumstances CSPY will be
recommended if an adenoma is detected during FSIG
and that if they are unwilling to accept referral to CSPY,
they should have a different form of screening.
FSIG—Other Issues. FSIG use in the United States
has been decreasing in the recent decade, coincident with
a rise in CSPY usage. An analysis of Medicare data from
the years 1993 to 2002 demonstrated a 54% decrease in
sigmoidoscopy use between the earliest and latest periods
studied and a more than 6-fold increase in CSPY usage
over the same time frame.103 Other data from endoscopic
facilities across the United States collected and analyzed
by investigators from the Centers for Disease Control
and Prevention estimated that approximately 2.8 million
FSIG examinations and 14.2 million CSPY examinations
were performed in 2002.104 Low reimbursement and a
shortage of adequately trained examiners are 2 barriers to
the availability of FSIG.30,105 In settings where reimburse-
ment rates have not been a concern and where nurse
endoscopists have been employed, high rates of FSIG
utilization have been achieved.106
FSIG—Conclusion and Recommendations. FSIG can re-
sult in the identification of the majority of prevalent CRC
at the time of screening, when the examination reaches
the splenic flexure or beyond 40 cm as a reasonable target
for insertion and when adenomas in the distal colon are
used as an indication for the need for CSPY. Although
the appropriate interval between normal examinations is
uncertain, FSIG is recommended to be performed for
screening every 5 years in most clinical settings due to
concerns about exam quality and completeness. FSIG can
be performed alone, or consideration can be given to
combining FSIG performed every 5 years with a highly
sensitive gFOBT or FIT performed annually. In high-
quality centers (such as the program operated by Kaiser
Permanente in California) where procedures are con-
ducted by properly trained and experienced endoscopists
who document regular insertion beyond 40 cm with a
good bowel preparation, a 10-year interval between neg-
ative exams may be reasonable.
Individuals should be informed about the limitations
of FSIG, including the fact that it examines only the
distal colon; that there is a risk, albeit small, of perfora-
tion; and that they may experience discomfort during
and after the examination. Patients should also under-
stand that the examination achieves higher quality when
bowel cleansing follows the same protocol as that for
CSPY. Finally, patients should be informed that positive
test findings will need to be followed up with CSPY.
CSPY. CSPY is one of the most commonly per-
formed medical procedures in the United States, with
estimates of up to 14 million procedures performed in
2003.104 CSPY allows direct mucosal inspection of the
entire colon from the appendiceal orifice to the dentate
line and same-session biopsy sampling or definitive treat-
ment by polypectomy in the case of precancerous polyps
and some early-stage cancers.
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The modern colonoscope is capable of examining the
entire bowel, with the examination terminating at the
cecum. Patients generally adopt a liquid diet one or more
days before the examination, followed by either ingestion
of oral lavage solutions or saline laxatives to stimulate
bowel movements until the bowel is clean. Proper bowel
preparation is a critical element in the accuracy and
cost-effectiveness of screening with CSPY.107 It is com-
mon for the patient to receive a mild sedative prior to the
procedure, but it is not essential for those who tolerate
the procedure with only mild discomfort.108
CSPY—Efficacy and Test Performance. There are no
prospective, randomized controlled trials of screening
CSPY for the reduction in incidence or mortality of CRC;
however, because CSPY is used to evaluate other positive
screening tests, there is evidence to indicate that CSPY
and polypectomy result in incidence reductions in ran-
domized controlled trials of other screening tests. The
University of Minnesota randomized controlled trial of
FOBT observed a 20% reduction in incidence of CRC,
which the authors attribute to CSPY and polypectomy in
patients with a positive FOBT.7 In a randomized con-
trolled trial of FSIG versus no screening and with fol-
low-up CSPY and polypectomy performed for any polyp
detected at sigmoidoscopy, the screening group experi-
enced an 80% incidence reduction in CRC.79
Case-control studies cited above of sigmoidoscopy and
polypectomy in screening populations also are consid-
ered to provide supporting evidence for CSPY because of
the similarity of the examinations in the distal colon. In
a case-control study of CSPY in the US VA population,
CSPY in symptomatic patients was associated with a 50%
reduction in mortality.109
The evaluation of incidence rates of CRC in adenoma
cohorts after baseline CSPY and polypectomy is another
form of evidence commonly cited to support CSPY for
CRC screening. In the National Polyp Study, the inci-
dence of CRC after clearing CSPY was reduced by 76% to
90% compared with 3 nonconcurrent reference popula-
tions.110 In an Italian adenoma cohort study with re-
moval of at least one adenoma 5 mm, there was an 80%
reduction in CRC incidence compared with expected in-
cidence in a reference population.111 However, not all
studies have shown the same level of protection. Com-
bined data from 3 US chemoprevention trials showed
incidence rates of CRC after clearing CSPY approximately
4 times that seen in the National Polyp Study, with no
reduction in CRC incidence compared with data from the
Surveillance Epidemiology and End Results (SEER) da-
tabase in the United States,112 and 2 US dietary interven-
tion trials also showed higher rates of incident CRC after
clearing CSPY than were observed in the National Polyp
Study.113,114 These differences may reflect exclusion of
patients with sessile adenomas 3 cm in the National
Polyp Study, more effective baseline clearing (13% of
patients in the National Polyp Study had 2 or more
baseline CSPY to complete clearing), or unmeasured dif-
ferences in the average quality of CSPY between the
studies.
Overall, the data support the conclusion that CSPY
with clearing of neoplasms by polypectomy has a signif-
icant impact on CRC incidence and thus, by extension,
mortality. The magnitude of the protective impact is
uncertain; it is not absolute, nor are apparent failures
well understood. In a study of 35,000 symptomatic pa-
tients in Manitoba who had undergone a negative CSPY
and who then were followed for 10 years, the investiga-
tors observed significant reductions in CRC incidence
over time, but the incidence reductions were less than
50% for each of the first 5 years and no more than 72% by
10 years. These findings suggest detection failures during
the initial, apparently normal, CSPY.
CSPY—Benefits, Limitations, and Harms. A principal
benefit of CSPY is that it allows for a full structural
examination of the colon and rectum in a single session
and for the detection of colorectal polyps and cancers
accompanied by biopsy or polypectomy. All other forms
of screening, if positive, require CSPY as a second
procedure.
Patient surveys indicate that patients willing to un-
dergo invasive testing tend to choose CSPY as their pre-
ferred test.71 In addition to being a complete examination
of the colon, individuals may also regard sedation during
the procedure as an advantage. Patients in the same
practice who had undergone unsedated FSIG screening
were more than twice as likely to say that they would not
return for additional screening compared with those who
had undergone CSPY with sedation.100
CSPY has several limitations. It requires one or more
days of dietary preparation and bowel cleansing, usually
a day dedicated to the examination, and because of se-
dation, a chaperone is needed for transportation. It is an
invasive procedure, and surveys indicate that a significant
percentage of adults prefer other noninvasive options for
CRC screening.71,115,116 Effective performance of the pro-
cedure is dependent on thorough bowel preparation,
which is often perceived as the most unpleasant part of
the CSPY process by those who have undergone the test.
Limitations with regard to detection of neoplasia have
been previously discussed, and the fact that CSPY is
operator skill dependent is another significant limitation.
Patients are generally poorly informed about the problem
of variable performance of the procedure and are un-
aware of the skill level of their endoscopists. Formal
quality assurance programs do not exist, and the current
reimbursement system for CSPY does not reward careful
examination but tends to reward rapidly performed ex-
aminations and repeated examinations at unnecessarily
short intervals.117 Polypectomy is sometimes ineffective
in eradicating polyps, a factor that has been implicated as
the cause of up to 25% of interval cancers.118,119 Finally,
CSPY is not an infallible “gold standard.” Controlled
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studies have shown the CSPY miss rate for large adeno-
mas (10 mm) to be 6% to 12%.120,121 The reported CSPY
miss rate for cancer is about 5%.120,122
CSPY can result in significant harm, most often asso-
ciated with polypectomy, and the most common serious
complication is postpolypectomy bleeding. The risk of
postpolypectomy bleeding is increased with large polyp
size and proximal colon location; however, small polyp
bleeds are more numerous than large polyp bleeds be-
cause small polyps are so numerous. Another significant
risk associated with CSPY is perforation. Perforation in-
creases with increasing age and the presence of divertic-
ular disease and was recently estimated to occur in 1 in
500 of a Medicare population and approximately 1 in
1000 screened patients overall.123 Because of the age
effect, perforation rates measured in the Medicare popu-
lation may overestimate the overall risk of perforation in
CSPY; however, a large study in the Northern California
Kaiser Permanente population also identified a perfora-
tion rate of 1 in 1000.98 In addition, cardiopulmonary
complications such as cardiac arrhythmias, hypotension,
and oxygen desaturation may occur, although these
events rarely result in hospitalization. Cardiopulmonary
complications represent about one half of all adverse
events that occur during CSPY and usually are related to
sedation.124 Thus, while screening CSPY has established
benefits with regard to the detection of adenomas and
cancer, complications related to CSPY are a significant
public health challenge.
Quality Assurance. Recent publications have high-
lighted criteria for best practices and important quality
indicators for CSPY.124–126 High-quality CSPY depends
on (1) appropriate training and experience; (2) proper
documentation of risk assessment; (3) complete exam to
the cecum with adequate mucosal visualization and
bowel preparation; (4) ability to detect and remove polyps
safely; (5) documentation of polypoid lesions and meth-
ods of removal; (6) timely and appropriate management
of adverse events; (7) appropriate follow-up of histopa-
thology findings; and (8) appropriate recommendation
for surveillance or repeat screening based on published
guidelines. Although CSPY is commonly used for screen-
ing, diagnosis, and therapy, until recently there was no
standardized reporting system for this procedure. To
enhance clear communication about CSPY findings be-
tween health care professionals and to facilitate quality
improvement programs, the Quality Assurance Task
Group of the National Colorectal Cancer Roundtable
developed a reporting and data system for CSPY based on
previously published continuous quality improvement
indicators.126
CSPY—Other Issues. CSPY in the United States is
performed by the overwhelming majority of gastroenter-
ologists, most colorectal surgeons, many general sur-
geons, and a small percentage of primary care physicians.
CSPY volumes have risen steadily in the United States,
while volumes for FSIG and DCBE have declined sub-
stantially in the past decade, and FOBT has remained
relatively stable, although a small decline in the rate was
observed among women.8,127 CSPY is offered in the vast
majority of American hospitals and is also widely per-
formed in ambulatory surgery centers and in physicians’
offices in some parts of the country. A recent survey of
American colonoscopists suggested that capacity could
be increased from the present 14 million annual proce-
dures to 22 million with currently available resources,104
although the methodology behind this estimate has been
criticized,128 and other estimates of capacity are less op-
timistic regarding capacity.129,130 In the short term, CSPY
capacity appears sufficient to handle slow increases in
demand for the majority of the US population, although
the capacity to handle a sharp increase in demand for
screening or diagnostic/therapeutic CSPY overall is un-
certain and likely highly variable geographically.
Some of the limitations in the availability of CSPY for
screening potentially could be overcome by more appro-
priate use of surveillance CSPY after polyp resection,
which has been shown to be excessive among gastroen-
terologists, and particularly among general surgeons and
primary care physicians.117,131 Excessive rates of short-
term follow-up after polypectomy, especially for small
lesions, also likely diminish the cost-effectiveness of
CSPY. For these reasons, the ACS and USMSTF recently
updated and further clarified recommendations for post-
polypectomy surveillance.25 The case against serial short-
term follow-up strategies rests on observations that over
the short term the risk of significant growth of adenomas
is quite low. However, because there is uncertainty about
the natural history of small colorectal adenomas and
perhaps because of a desire to err on the side of prudence,
a significant percentage of clinicians recommends fol-
low-up intervals that are considerably shorter than rec-
ommended, and surveillance intervals often are not ad-
justed for subsequent negative findings.117 Recent
guideline recommendations continue to expand the in-
terval between follow-up CSPY examinations in patients
with low-risk adenomas.26
CSPY—Conclusions and Recommendations. The appro-
priate interval between negative CSPY screening exams is
uncertain because of lack of long-term follow-up data. At
present, CSPY every 10 years is an acceptable option for
CRC screening in average-risk adults beginning at age 50
years. Individuals should be informed about the limita-
tions of CSPY, including the fact that it may miss some
cancers and significant adenomas, and that there is a risk,
albeit small, of perforation, hemorrhage (following
polypectomy), subsequent hospitalization, and in very
rare circumstances, more serious harm. A full bowel
cleansing is necessary prior to CSPY. Sedation usually is
used to minimize discomfort during the examination,
and thus a chaperone is required to provide transporta-
tion after the examination.
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Imaging Examinations of the Colon and
Rectum—DCBE and CTC
DCBE. The DCBE, sometimes referred to as air-
contrast barium enema, evaluates the colon in its entirety
by coating the mucosal surface with high-density barium
and distending the colon with air introduced through a
flexible catheter that is inserted into the rectum. Multiple
radiographs are acquired while varying the patient posi-
tion during direct fluoroscopic evaluation and subse-
quently with conventional radiographic equipment. Co-
lonic preparation, usually a 24-hour dietary and laxative
regimen, is essential for an optimal examination. Seda-
tion is not utilized, and the duration of the procedure
averages about 20 to 40 minutes. Patients may experience
mild to moderate discomfort during and after the pro-
cedure, but a prompt return to normal activity is typical.
DCBE was contemporaneously adopted as a CRC
screening option by the Multi-Society Gastroenterology
Consortium and the ACS in 1997 and has continued to
be included among the recommended screening options
in periodic updates of those guidelines12,17,24,132 as well as
those of the US Preventive Services Task Force.21 It is also
considered appropriate for screening by the ACR.133 CRC
screening of the average-risk population with DCBE also
has been a designated Medicare benefit since 1997.134
DCBE—Efficacy and Test Performance. There have been
no randomized controlled trials evaluating the efficacy of
DCBE as a primary screening modality to reduce inci-
dence or mortality from CRC in average-risk adults, and
there also are no case-control studies evaluating the per-
formance of DCBE. Further, the existing literature de-
scribing the test performance of DCBE also is limited by
study designs that are retrospective and commonly do
not report findings from an asymptomatic or average-
risk population.135,136 In some reports, asymptomatic in-
dividuals were selected for investigation during neoplasm
surveillance or after a prior screening test (eg, FSIG or
FOBT). Finally, similar to the literature related to other
CRC screening technologies, the DCBE literature varies
considerably in terms of measurement and outcome met-
rics (ie, polyps, cancers, all neoplasms, adenomas, size
categorizations, etc), and these measurements may be
estimated by lesion or by population.
Most studies evaluating the cancer detection capability
of DCBE utilized a methodology in which all patients in
an institution- or population-based database that had
been diagnosed with CRC were assessed for a history of a
prior DCBE within a defined time frame, the length of
which was not consistent between studies but usually
ranged from 2 to 5 years. The assumption was that
missed cancers on DCBE would subsequently be clini-
cally detected. The majority of these studies showed sen-
sitivity for cancer of 85% to 97%.137–150
Review of the literature concerning the performance of
DCBE for polyps is more difficult due to the described
biases and heterogeneity of study design; in particular,
the target lesion and thresholds considered clinically sig-
nificant often varied based upon size and/or morphology.
Two studies involving truly asymptomatic individuals
were performed in surveillance groups with a history of
prior adenoma removal.151,152 These demonstrated sensi-
tivities of 48% (n  23) for adenomas 1 cm and 73% (n
 56) for adenomas 7 mm, respectively. It should be
noted that in the former study the DCBE detected 75% (6
of 8) with advanced histology.153
DCBE—Benefits, Limitations, and Harms. The potential
benefits derived from the DCBE are that it evaluates the
entire colon in almost all cases and can detect most
cancers and the majority of significant polyps. DCBE also
provides an opportunity for a full structural examination
for individuals for whom CSPY has either failed or is
contraindicated.
DCBE has several limitations. The acceptability of
DCBE may be limited by the requirement for extensive
colonic preparation, and some patients experience dis-
comfort during and after the procedure. Suboptimal
preparation can reduce both sensitivity and specificity.
Further, there is no opportunity for biopsy or polypec-
tomy, and any individual with findings of polyps6 mm
on DCBE should undergo CSPY. The lower sensitivity for
significant adenomas when compared with CSPY may
result in less favorable outcomes regarding morbidity
and mortality from CRC. DCBE is also limited by the
operator dependence of the radiologist or technologist
performing the examination, as well as by the radiologist
interpreting the examination. DCBE is a relatively safe
procedure with a lower perforation rate when compared
with CSPY (1 of 25,000 vs 1 of 1000 to 2000).154
Quality Assurance. The DCBE is a full structural
examination of the entire colon that can be performed by
radiologists or radiology residents and trained techni-
cians under the supervision of a radiologist. Factors that
can affect the quality of the DCBE examination include
(1) ability to fully evaluate the entire colon due to lack of
retained barium or collapse of segments of the colon, (2)
adequacy of the bowel preparation, (3) patient’s ability to
stand and be imaged in prone and supine positions, and
(4) reader’s experience in interpretation. Caution is ad-
vised when performing a DCBE on the same day after
polypectomy to avoid a perforation. The ACR has pub-
lished guidelines that detail the basic requisites for a
high-quality examination,155 as well as a quality assur-
ance manual for the DCBE.155 Interaction with referring
physicians to correlate radiologic findings with endo-
scopic and/or surgical outcomes may also be an effective
ongoing quality assurance in clinical practice.
DCBE—Other Issues. It is likely that the decline in
the use of DCBE for CRC screening in average-risk adults
will continue.156–158 This decline in the utilization of
DCBE has had an impact on training programs, as radi-
ology residents have had less opportunity to develop the
necessary skills to perform the procedure properly. More-
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over, although there likely are sufficient numbers of ra-
diologists in clinical practice who are available currently
to perform DCBE studies, there has been a decline in
radiologists’ enthusiasm for the DCBE due to its labor-
intensive nature, the low reimbursement rate, and greater
interest in newer and more complex technologies such as
computed tomography (CT) and magnetic resonance im-
aging (MRI). Based on these trends, it is likely that in the
next 5 years, there will be even fewer radiologists ade-
quately trained to perform this procedure due to the low
volume of DCBE studies currently being requested, as
well as low professional interest. At present, the DCBE
remains an option for direct imaging of the entire colon
and may be of particular value where CSPY resources are
limited or CSPY is contraindicated or less likely to be
successful (eg, prior incomplete CSPY, prior pelvic sur-
gery, etc).
DCBE—Conclusions and Recommendations. DCBE every
5 years is an acceptable option for CRC screening in aver-
age-risk adults aged 50 years and older. Discussions with
patients should include a description of the test character-
istics, the importance of adherence to a thorough colon
cleansing, test accuracy, the likelihood of a positive test, and
the need for subsequent CSPY if the test is abnormal. The
choice of DCBE for screening can be made on an individual
basis, depending on factors such as personal preference,
cost, and the local availability of trained radiologists able to
offer a high-quality examination.
CTC. CTC, also referred to as virtual coloscopy, is
a minimally invasive imaging examination of the entire
colon and rectum. CTC uses CT to acquire images and
advanced 2-dimensional (2D) and 3-dimensional (3D)
image display techniques for interpretation. Since its
introduction in the mid-1990s, there have been rapid
advancements in CTC technology. Multidetector CT now
permits image acquisition of thin 1- to 2-mm slices of the
entire large intestine well within breath-hold imaging
times. Computer imaging graphics allow for visualization
of 3D endoscopic flight paths through the inside of the
colon, which are simultaneously viewed with interactive
2D images. The integrated use of the 3D and 2D tech-
niques allows for ease of polyp detection, as well as
characterization of lesion density and location. The 2D
images also allow for limited evaluation of the extraco-
lonic structures.
Adequate bowel preparation and gaseous distention of
the colon are essential to ensure a successful examina-
tion. Patients typically undergo full cathartic preparation
along with a clear liquid diet the day before the study,
similar to the requirements for CSPY. Tagging of residual
solid stool and fluid with barium and/or iodine oral
contrast agents is being increasingly used and validated
in large trials. At CT, a small-caliber rectal catheter is
inserted into the rectum, followed by automated or man-
ual insufflation of room air or carbon dioxide. Intrave-
nous contrast generally is not given to patients undergo-
ing screening but can be helpful in some patients with
more advanced symptoms. Typically, the entire proce-
dure on the CT table takes approximately 10 minutes,
with no sedation or recovery time needed. Research into
noncathartic approaches to minimize the bowel prepara-
tion is under way, but this technique has not yet been
validated in a multicenter screening trial.159–161 However,
under conditions where same-day or next-day referral for
CSPY would be possible, one drawback of noncathartic
CTC is that a cathartic bowel preparation would still be
required prior to removal of polyps.
CTC—Efficacy and Test Performance. No prospective,
randomized, controlled clinical trial has been initiated
(nor is one planned) to directly demonstrate the efficacy
of CTC in reducing mortality from CRC. Given the cu-
mulative body of evidence in support of CRC screening
for reducing mortality and the value of polypectomy in
reducing incidence, studies of CTC have focused on the
detection of advanced neoplasia.
The test performance characteristics of CTC for polyp
detection are derived by using optical colonoscopy (OC)
as the reference standard. Early single-center CTC clinical
trials involving small, polyp-rich cohorts162–164 provided
encouraging initial results and served as proof of concept
that paved the way for larger multicenter screening trials.
Two early trials by Cotton et al165 and Rockey et al166
included approximately 600 subjects each and observed
per-patient sensitivity for large polyps of 55% and 59%,
respectively. However, these 2 studies did not evaluate
screening in an asymptomatic population, nor did they
apply the latest CTC techniques. A more recently initi-
ated multi-institutional screening trial using more ad-
vanced CTC techniques demonstrated more favorable
performance. Pickhardt et al studied 1233 asymptomatic
adults and introduced the techniques of stool tagging
and primary 3D polyp detection, neither of which were
used in the 2 earlier multi-institutional trials.167 This trial
reported a 94% sensitivity for large adenomas, with a
per-patient sensitivity for adenomas 6 mm of 89%.
In 2005, 2 meta-analyses reviewed the cumulative pub-
lished CTC performance data, including both high-risk
and screening cohorts, with one analysis representing 33
studies on 6393 patients.168,169 On a per-patient basis,
pooled CTC sensitivity and specificity for large (10
mm) polyps was found to be 85% to 93% and 97%,
respectively. Pooled sensitivity and specificity for detec-
tion of small polyps (6 to 9 mm) was 70% to 86% and 86%
to 93%, respectively. Of note, the pooled CTC sensitivity
for invasive CRC was 96%,168 comparable with the re-
ported sensitivity for OC.119,121
There also are a number of CTC trials currently in
progress within the United States and Europe. Initial
results from smaller screening trials utilizing 3D polyp
detection by Cash et al170 and Graser et al171 have shown
CTC performance characteristics similar to that of Pick-
hardt et al, providing at least a measure of independent
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validation for this screening technique. Also of particular
interest is the recently completed ACRIN Study 6664:
National CT Colonography Trial, which is sponsored and
funded by the National Cancer Institute. The primary
aim of this trial was to assess CTC performance for large
adenomas and advanced neoplasia in a large screening
cohort of 2500 patients across 15 institutions. State-of-
the-art techniques included oral contrast tagging, colonic
distention with automated carbon dioxide delivery, mul-
tidetector row CT (16 slice) with thin collimation, and
both 2D and 3D polyp detection on dedicated CTC
software systems. Preliminary findings announced at the
2007 annual meeting of ACRIN on September 28, 2007,
were consistent with other recent studies using state-of-
the-art techniques.
Beyond validation, a recent study demonstrated the
efficacy of CTC to select patients who would benefit from
therapeutic polypectomy. Kim et al recently reported
comparative results from primary CTC (with selective
recommendation for therapeutic CSPY) and primary OC
screening arms among 3120 and 3163 mostly asymptom-
atic adults, respectively.172 Although this study did not
randomize participants to CTC versus OC, apart from a
slightly higher proportion of individuals with a family
history in the OC group, the 2 groups were similar.
Similar rates of advanced neoplasia were found in each
group, with 3.2% in the CTC group and 3.4% in the OC
group.172
CTC—Benefits, Limitations, and Harms. CTC provides a
time-efficient procedure with minimal invasiveness. No
sedation or recovery time is required, nor is a chaperone
needed to provide transportation after the procedure.
Time permitting, patients can return to work on the
same day. However, some limitations to CTC exist. At
this time, reimbursement for screening CTC is very lim-
ited, although 47 states now offer Medicare reimburse-
ment for diagnostic CTC where the clinical indication is
limited to incomplete OC.173 However, because reim-
bursement for screening still is uncommon, the current
professional capacity to deliver CTC also is limited, al-
though capacity is expected to increase when third-party
payers begin providing reimbursement for screening.
As an “imaging-only,” nontherapeutic evaluation, pa-
tients with polyps of significant size will require thera-
peutic CSPY for subsequent polypectomy. CTC requires
the same full cathartic bowel preparation and restricted
diet as OC, which may decrease patient adherence. How-
ever, with this approach, same-day polypectomy can be
offered without the need for an additional bowel prepa-
ration, although this convenience for patients requires
careful coordination between radiology and gastroenter-
ology departments.174
CTC is similar to endoscopy and DCBE with respect to
the quality of interpretation being highly operator de-
pendent, and thus initiatives toward training and certi-
fication are important. Detection of flat lesions has been
variable, ranging from sensitivities of 13% to 65% in early
CTC studies175 to 80% when using multidetector CT and
combined 3D-2D polyp detection.176 However, debate
continues over the prevalence and significance of flat
colorectal lesions.177–179
The accuracy of CTC is influenced by lesion size, and
the sensitivity and specificity of CTC improves with polyp
size. The accuracy of CTC in measuring polyp size is of
particular importance since accurate size estimation is
critical for appropriate patient management and for min-
imizing the false-positive rate. While earlier studies using
rudimentary software applied to wide-slice thicknesses
and 2D images showed poor concordance with prefix-
ation polyp size,180 modern CT technology producing 3D
images results in more accurate size estimates.181–183The
ability to ensure consistent polyp size measurements dur-
ing examinations is a high priority for quality-assurance
initiatives since it will influence referrals for polypec-
tomy. Pickhardt et al showed that specificity (when pol-
yps were matched for size) was 97.4% for lesions _1 cm
but declines to 84.5% for all lesions to all lesions
_6mm.167 The incremental increase in the falsepositive
rate associated with polyps between 6 to 8 mm could add
significantly to the cost of screening, and thus it will be
important to monitor sensitivity and specificity in the
clinical setting and identify strategies to improve speci-
ficity without diminishing sensitivity. There is contro-
versy over the long-term potential harms associated with
radiation dose effects from CT examinations. One aspect
of this controversy relates to risk-estimation models, and
the other pertains to the long-term risk of cancer from
single and repeated medical imaging exposures.184,185
While current estimates of the potential cancer risk re-
lated to low-dose radiation exposures during medical
procedures derive from linear nonthreshold models
based on long-term outcomes in survivors of acute radi-
ation doses from atomic weapons, there is disagreement
over whether this model truly is applicable to periodic
exposures from medical imaging.186 In a recent position
statement issued by the Health Physics Society, the
health effects of low-dose radiation exposure (defined as
below 50 to 100 mSv—a threshold many times higher
than typical CTC levels) were considered to be “either too
small to be observed or are nonexistent.”187 Nevertheless,
although this risk may be theoretical, there is a growing
concern that more individuals are receiving multiple di-
agnostic evaluations with ionizing radiation over a life-
time and that for some individuals the doses over a
lifetime can reach levels that are sufficiently high to be of
concern. It is important to put these issues into context
with respect to screening with CTC. Using the linear,
no-threshold radiation-risk estimate, a CTC examination
in a 50-year-old individual with an estimated organ dose
to the colon of 7 to 13 mSv (65 mAs) is estimated to add
an additional 0.044% to the lifetime risk of colon can-
cer.188 Because organ radiosensitivity declines with in-
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creasing age, this organ dose is halved for the same
examination taking place at age 70 years. In this same
evaluation, the additional lifetime risk of cancer in any
site associated with a single CTC examination at age 50
years was 0.14%, although the authors stated with opti-
mized techniques this risk could be reduced by a factor of
5- to10-fold. More efficient dose protocols using 50 mAs
on 4DCT, similar to the ACR-defined protocols, have
demonstrated decreased estimated organ dose ranges of 5
to 8 mSv.189 While acknowledging there is uncertainty
about potential harms from single or multiple CTC
screening examinations, current ACR quality metrics for
CTC define low-dose parameters as a best practice for
minimizing risk to patients.190 Since CTC is a minimally
invasive test, the risk for colonic perforation during
screening is extremely low. In the collective experience of
the International Working Group on Virtual Colonos-
copy, there were no cases of perforation in over 11,000
screening CTC examinations, and out of nearly 22,000
total CTC examinations (screening and diagnostic), there
was only one symptomatic perforation, corresponding to
a symptomatic perforation rate of 0.005%.191 Some stud-
ies of symptomatic patients, however, have reported
higher perforation rates, ranging from 0.03% (1 in 3,400
patients) to 0.06% (1 in 1,700 patients).192,193Colonic dis-
tention with lowpressure carbon dioxide delivery may be
safer than insufflation of room air.191 Rates of perfora-
tion are part of the quality metrics being collected by the
ACR. Because CTC produces an image not only of the
colon but also the upper and lower abdomen, there is a
chance that incidental extracolonic findings will be ob-
served. Although the overall rates of extracolonic findings
have been reported to range from 15% to 69%, the inci-
dence of clinically significant extracolonic findings at
CTC has ranged from 4.5% to 11% in various patient
cohorts.194–197In an asymptomatic screening population,
the incidence of unsuspected but potentially important
extracolonic findings is approximately 4.5%, but findings
of minimal or moderate potential clinical significance,
such as cholelithiasis (6%) and nephrolithiasis (8%), are
more common.197 While there are potential benefits from
serendipitous findings, there also are associated risks and
costs that need to be considered when these findings are
false positives. These include further radiologic imaging
and, thus, added organ dose, potential for adverse out-
comes associated with tissue sampling for abnormalities
that are not resolved with additional imaging, as well as
the direct and indirect costs to the patient. The imple-
mentation of structured reporting of extracolonic find-
ings and monitoring trends in subsequent diagnostic
workups and adherence with quality metrics are being
evaluated through the National Radiology Data Registry
(NRDR), the ACR’s national data warehouse.
Quality Assurance. Similar to the call to action for
measuring quality of CSPY,198 the implementation of
CTC will require quality metrics to be defined and im-
plemented in clinical practice. Quality of CTC examina-
tions will depend on (1) proper bowel preparation; (2)
adequate insufflation of the colon and appropriate use of
CTC technique parameters at image acquisition; (3) ad-
equate training of the interpreting physician in the use of
2D and 3D image display techniques; and (4) documen-
tation of clinically significant colonic and extracolonic
lesions to referring physicians. In 2005, the ACR Practice
Guideline for the Performance of Computed Tomogra-
phy (CT) Colonography in Adults was published, encom-
passing the techniques, quality control, clinical uses,
training, and communication of results for CTC.190 An
update of these guidelines is planned following publica-
tion of the results of the ACRIN CTC screening trial. In
2006, the ACR Colon Cancer Committee outlined prac-
tice-based quality metrics for CTC, encompassing process
measures of CTC technique and image quality; patient
preparation; and outcomes measures such as rates of true
positives, colonic perforation, and incidence of extraco-
lonic findings. These quality metrics are to begin a pilot
phase in late 2007, with data entry in the National Ra-
diology Data Register (NRDR) database. The ACR has
begun construction of an interactive hands-on training
facility for CTC and will begin training courses in early
2008. A process for individual certification and profi-
ciency is being evaluated.
CTC—Other Issues. Standardization of the evolving
technology and consensus related to the reporting of
findings will be essential for effective implementation of
CTC screening. A consensus statement of a standardized
reporting structure for CTC findings was recently pub-
lished, modeled after the Breast Imaging Reporting and
Data System’s (BI-RADS) reporting of mammography.199
This reporting structure, termed the “CT Colonography
Reporting and Data System (C-RADS),” describes how to
report lesion size, morphology, and location, with a sum-
mary category score per patient.
The management of CTC findings is an important part
of a CTC screening program. At this time, there is con-
sensus that all patients with one or more polyps10 mm
or 3 or more polyps 6 mm should be referred for
CSPY.77,200 The management of patients with fewer pol-
yps (3) in which the largest polyp is 6 to 9 mm remains
controversial. Such polyps are routinely removed if found
at OC because of the opportunity and the risk, albeit low,
of advanced neoplasia. However, in studies that have
been limited to screening cohorts, among individuals
whose largest polyp is 6 to 9 mm in size, the prevalence
of advanced features tends to be low (3.4% to 6.6%).201,202
At this time, there is ongoing research using CTC sur-
veillance to evaluate the natural history of polyps in this
size range. Based on expert consensus and until further
evidence is available to provide additional guidance, a
reasonable approach at this time for patients with 6- to
9-mm polyps identified on CTC is to offer therapeutic
CSPY. Patients who decline referral to CSPY or who are
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not good candidates for CSPY should be offered surveil-
lance with CTC.
Optimal management of patients whose largest polyp
is 6 mm detected on CTC is uncertain. Experts from
the American Gastroenterological Association, the Amer-
ican College of Gastroenterology, and the ACR have re-
ported a range of policies on how to handle these le-
sions.190,203,204 There is general agreement that the risk of
advanced features in patients whose largest polyp is 5
mm is very low. In a recent study that is able to provide
this estimate in a screening cohort, the prevalence of
advanced neoplasia in patients whose largest polyp was
5 mm was 1.7% (D.A.L., personal communication, De-
cember 14, 2007).202 At this time, there is a pressing need
for multidisciplinary consensus on the reporting and
clinical management of patients whose largest polyp is
6 mm.
CTC—Conclusions and Recommendations. In terms of
detection of colon cancer and advanced neoplasia, which
is the primary goal of screening for CRC and adenoma-
tous polyps, recent data suggest CTC is comparable to
OC for the detection of cancer and polyps of significant
size when state-of-the-art techniques are applied.
In previous assessments of the performance of CTC,
the ACS concluded that data were insufficient to recom-
mend screening with CTC for average-risk individuals.19
Based on the accumulation of evidence since that time,
the expert panel concludes that there are sufficient data
to include CTC as an acceptable option for CRC
screening.
Screening of average-risk adults with CTC should com-
mence at age 50 years. The interval for repeat exams after
a negative CTC has not been studied and is uncertain.
However, if current studies confirm the previously re-
ported high sensitivity for detection of cancer and of
polyps 6 mm, it would be reasonable to repeat exams
every 5 years if the initial CTC is negative for significant
polyps until further studies are completed and are able to
provide additional guidance. Until there is more research
on the safety of observation, patients whose largest polyp
is 6 mm or greater should be offered CSPY. CTC surveil-
lance could be offered to those patients who would ben-
efit from screening but either decline CSPY or are not
good candidates for CSPY for one or more reasons. How-
ever, if CSPY is contraindicated because the patient is not
likely to benefit from screening due to life-limiting co-
morbidity, then neither CTC nor any other CRC screen-
ing test would be appropriate.
Conclusion
There is compelling evidence to support screening
average-risk individuals over age 50 years to detect and
prevent CRC. Screening of average-risk individuals can
reduce CRC mortality by detecting cancer at an early,
curable stage and by detecting and removing clinically
significant adenomas. No CRC screening test is perfect,
either for cancer detection or adenoma detection. Each
test has unique advantages, each has been shown to be
cost-effective,205–208 and each has associated limitations
and risks. Patient preferences and availability of resources
play an important role in the selection of screening tests.
In this update of the guidelines for CRC screening, we
have placed an emphasis on the value of preventing CRC,
sought to address the importance of test sensitivity in the
presence of low rates of programmatic screening, and
attempted to provide improved guidance about test char-
acteristics and quality issues to referring clinicians. Ide-
ally, screening should be supported in a programmatic
fashion that begins with risk stratification and the results
from an initial test and continues through proper fol-
low-up based on findings. The effectiveness of any single
test or combination of tests depends on high rates of
programmatic adherence and quality.
Based on differing incidence rates and observations of
different patterns of polyp and cancer distribution in
certain subsets of patients (ie, the elderly, women, ethnic
minorities, etc), some experts have suggested that these
groups may require different screening recommenda-
tions.209,210 The expert panel reviewed and discussed the
evidence and rationale for and against including different
screening recommendations in this update for various
demographic subgroups that have been shown to be at
somewhat higher or lower than average risk for disease or
proximal lesions. After some consideration, this issue was
postponed for further consideration at a later time for a
number of reasons, although principally because (1) there
are no current data to indicate that CRC incidence and
mortality in these groups would be positively impacted
by tailored screening recommendations; and (2) screen-
ing rates among all groups remain low under existing
guidelines, and providing different (and, in some cases,
more limited) screening options has the potential to
increase confusion, complexity, and workload and thus
might add additional barriers to screening that would
affect all groups. This is an area of research that the 3
organizations’ guidelines committees will continue to
monitor closely.
In this update of the CRC screening guidelines, we have
focused on screening in average-risk adults and have not
reviewed recent literature on CRC screening or surveillance
for individuals at increased and high risk. Individuals at
increased risk due to a history of adenomatous polyps; a
personal history of curative-intent resection of CRC; a fam-
ily history of either CRC or colorectal adenomas diagnosed
in a first-degree relative before age 60 years; or high risk due
to a history of inflammatory bowel disease of significant
duration or the presence of one of 2 hereditary syndromes
should continue to follow recommendations issued previ-
ously by the ACS or USMSTF.18,24 These recommendations
are summarized in Table 3.
There appears to be a clear need for institutionally
based quality assurance programs to improve the quality
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Table 3. Guidelines for Screening and Surveillance for the Early Detection of Colorectal Adenomas and Cancer in Individuals
at Increased Risk or at High Risk
Risk category Age to begin Recommendation Comment
Increased Risk—Patients with History of Polyps at Prior Colonoscopy
Patients with small
rectal hyperplastic
polyps26
— Colonoscopy or other
screening options at
intervals
recommended for
average-risk
individuals
An exception is patients with a hyperplastic
polyposis syndrome. They are at
increased risk for adenomas and
colorectal cancer and need to be
identified for more intensive follow-up.
Patients with 1 or 2
small tubular
adenomas with low-
grade dysplasia26
5 to 10 years after the
initial polypectomy
Colonoscopy The precise timing within this interval
should be based on other clinical factors
(such as prior colonoscopy findings,
family history, and the preferences of the
patient and judgment of the physician).
Patients with 3 to 10
adenomas, or 1
adenoma 1 cm, or
any adenoma with
villous features or
high-grade
dysplasia26
3 years after the initial
polypectomy
Colonoscopy Adenomas must have been completely
removed. If the follow-up colonoscopy is
normal or shows only 1 or 2 small
tubular adenomas with low-grade
dysplasia, then the interval for the
subsequent examination should be 5
years.
Patients with 10
adenomas on a
single examination26
3 years after the initial
polypectomy
Colonoscopy Consider the possibility of an underlying
familial syndrome.
Patients with sessile
adenomas that are
removed
piecemeal26
2 to 6 months to verify
complete removal
Colonoscopy Once complete removal has been
established, subsequent surveillance
needs to be individualized based on the
endoscopist’s judgment. Completeness
of removal should be based on both
endoscopic and pathologic assessments.
Increased Risk—Patients with Colorectal Cancer
Patients with colon
and rectal cancer
should undergo high-
quality perioperative
clearing 25
3 to 6 months after
cancer resection, if no
unresectable metastases
are found during surgery;
alternatively, colonoscopy
can be performed
intraoperatively.
Colonoscopy In the case of nonobstructing tumors, this
can be done by preoperative
colonoscopy. In the case of obstructing
colon cancers, CTC with intravenous
contrast or DCBE can be used to detect
neoplasms in the proximal colon.
Patients undergoing
curative resection
for colon or rectal
cancer23
1 year after the resection
(or 1 year following the
performance of the
colonoscopy that was
performed to clear the
colon of synchronous
disease)
Colonoscopy This colonoscopy at 1 year is in addition to
the perioperative colonoscopy for
synchronous tumors. If the examination
performed at 1 year is normal, then the
interval before the next subsequent
examination should be 3 years. If that
colonoscopy is normal, then the interval
before the next subsequent examination
should be 5 years. Following the
examination at 1 year, the intervals
before subsequent examinations may be
shortened if there is evidence of HNPCC
or if adenoma findings warrant earlier
colonoscopy. Periodic examination of the
rectum for the purpose of identifying
local recurrence, usually performed at 3-
to 6-month intervals for the first 2 or 3
years, may be considered after low
anterior resection of rectal cancer.
Increased Risk—Patients with a Family History
Either colorectal
cancer or
adenomatous polyps
in a first-degree
relative before age
60 years or in 2 or
more first-degree
relatives at any age24
Age 40 years, or 10 years
before the youngest
case in the immediate
family
Colonoscopy Every 5 years
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of CRC screening. This guideline update emphasizes is-
sues for quality assurance across colorectal screening
modalities, spanning training requirements, optimal
techniques to complete examination, screening intervals,
and appropriate recommendations for follow-up. In con-
trast, cost-effectiveness is not specifically discussed in this
document, based on the numerous complexities of ade-
quately addressing this topic, including understanding
real costs in different environments, differences in test
performance and interpretation, and wide variability of
screening intervals in different settings. It is hoped that
compliance with improvements in quality assurance will
both improve quality and promote cost-effectiveness.
Clearly, better definition of the target lesion of clinical
importance is needed across modalities. As new technol-
ogies evolve that detect but do not remove polyps, mul-
tidisciplinary consensus is needed to best manage a pa-
tient programmatically for follow-up polypectomy versus
surveillance intervals. Although there are some ongoing
studies of the natural history of small polyps, evidence-
based data will probably take 10 to 20 years to meaning-
fully translate into clinical practice recommendations. In
this interim, the current recommendations try to address
these issues with expert consensus based on existing data.
Multidisciplinary groups, such as the National Colorectal
Cancer Roundtable, may be able to serve as an effective
forum for the development of a consensus across special-
ties about the reporting and follow-up of small polyps.
In conclusion, it is our hope that these new recom-
mendations will facilitate increased rates of CRC screen-
ing and that referring clinicians find these new guidelines
ease some of the challenges they have experienced in
promoting CRC screening to their patients.
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